Treatment
Ruxolitinib clinical trials
We’re tracking 101 recruiting studies that include Ruxolitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06627335Recruiting
Eczema creams and pregnancy outcomes study
This study looks at women who used a topical eczema cream called ruxolitinib (Opzelura) or steroid creams during pregnancy. The goal is to compare pregnancy outcomes and baby health up to one year after birth.
Morrisville, North CarolinaAges 14 years+ - NCT03874052RecruitingPhase 1
Ruxolitinib plus venetoclax and azacitidine for relapsed AML
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Columbus, OhioAges 18 years+ - NCT07359859RecruitingPhase 2
Ruxolitinib to prevent GVHD in stem cell transplant
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Basking Ridge, New JerseyAges 18 years+ - NCT07464951RecruitingPhase 1
CART123 cells with or without ruxolitinib for AML
This trial tests a new type of immune cell therapy (CART123) alone or with a drug called ruxolitinib for children and young adults with AML that has come back or not responded to standard treatment. The goal is to see if this combination can help destroy leukemia cells.
Philadelphia, PennsylvaniaAges birth–29 years - NCT07548983RecruitingPhase 1
Ruxolitinib and azacitidine after stem cell transplant for acute myeloid leukemia
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
Portland, OregonAges 18 years+ - NCT06719024RecruitingPhase 2/Phase 3
Ruxolitinib cream for vitiligo on face and neck
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
Hong KongAges 18–85 - NCT06756061RecruitingPhase 2
Ruxolitinib and steroids for chronic graft-versus-host disease
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
Seoul, Banpo-daero/Seocho-guAges 19 years+ - NCT06824103RecruitingPhase 4
Study of ruxolitinib for chronic graft-versus-host disease in China
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
Hefei, AnhuiAges 12–100 - NCT06857240RecruitingPhase 2
Ruxolitinib cream for stubborn skin in dermatomyositis
This trial tests a cream called ruxolitinib for people with dermatomyositis whose skin symptoms haven't improved with standard treatments. It aims to see if this cream can reduce rash and activity when added to your current medications.
Cleveland, OhioAges 18–89 - NCT07085039RecruitingPhase 2
Ruxolitinib for previously treated idiopathic multicentric Castleman disease
This trial tests the drug ruxolitinib for people with idiopathic multicentric Castleman disease (iMCD) whose symptoms are not well controlled by standard anti-IL-6 therapy. Ruxolitinib is a pill taken by mouth that may help reduce inflammation and improve symptoms.
Philadelphia, PennsylvaniaAges 18–80 - NCT07128381RecruitingPhase 1/Phase 2
Axatilimab plus Ruxolitinib for Myelofibrosis and CMML
This trial tests a new combination of two drugs (axatilimab and ruxolitinib) for people with myelofibrosis or a related blood cancer called CMML. The goal is to see if the combination works better than standard treatments for these diseases.
Houston, TexasAges 18 years+ - NCT07153666Recruiting
Ruxolitinib cream for vitiligo: a real-world study
This study tests how well a cream called ruxolitinib works for vitiligo in real-world conditions. It looks at what factors might make the treatment more or less effective.
BeijingAges 12 years+ - NCT07219576RecruitingPhase 1/Phase 2
Study of Retifanlimab and Ruxolitinib for Certain Cancers
This trial tests a combination of two drugs, retifanlimab and ruxolitinib, for people with advanced kidney cancer (clear cell renal cell carcinoma) or lung cancer (non-small cell lung carcinoma) whose cancer has grown after previous treatment with a type of immunotherapy called PD-1/PD-L1 inhibitors. The goal is to see if this combination can help when standard treatments are no longer working.
La Jolla, CaliforniaAges Any age - NCT07228624RecruitingPhase 2
Ruxolitinib before, during, and after transplant for myelofibrosis
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Seattle, WashingtonAges 18–75 - NCT07252050RecruitingPhase 1/Phase 2
Ruxolitinib and half-matched transplant for severe sickle cell disease
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Aurora, ColoradoAges 12–45 - NCT07278856RecruitingPhase 1
Ruxolitinib plus CHOP for untreated T-follicular helper cell lymphoma
This trial tests adding an oral targeted drug called ruxolitinib to the standard CHOP chemotherapy for people newly diagnosed with a rare type of lymphoma. The goal is to see if this combination is safe and works well.
Duarte, CaliforniaAges 18 years+ - NCT07340138RecruitingPhase 1
Pelabresib and Ruxolitinib combo for myelofibrosis in Japan
This study tests adding a new drug (pelabresib) to the standard treatment (ruxolitinib) for Japanese people with myelofibrosis. The goal is to see if the combination helps control symptoms like an enlarged spleen.
Kamogawa, ChibaAges 18 years+ - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT03571321RecruitingPhase 1
Ruxolitinib plus chemotherapy for Ph-like B-ALL
This early-phase study tests whether adding ruxolitinib (a targeted medicine) to standard chemotherapy improves outcomes in adolescents and young adults with newly diagnosed Ph-like B-precursor acute lymphoblastic leukemia (ALL). It targets specific genetic features (“JAK-targetable signature”) thought to make the leukemia more responsive to JAK-blocking treatment.
Chicago, IllinoisAges 18–39 - NCT07588139RecruitingPhase 1
Testing two JAK inhibitor medicines in healthy adults
This early-stage study tests how two experimental medicines (povorcitinib by mouth and ruxolitinib cream on skin) work in healthy volunteers. Researchers will measure how these drugs move through your body and affect your skin to learn if they're safe and effective.
Dilworth, MinnesotaAges 18–65 - NCT02974647RecruitingPhase 2
Ruxolitinib for relapsed or hard-to-treat T/NK cell lymphoma
This trial studies ruxolitinib, a medicine that affects immune signaling, in people whose T-cell or NK-cell lymphoma has returned or hasn’t responded to treatment. It may help shrink lymphoma and improve symptoms after other therapies.
Miami, FloridaAges 18 years+ - NCT07317700RecruitingPhase 3
Study of a new pill for high-risk myelofibrosis
This trial is testing a new pill for people with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It aims to see if the drug can help manage the disease and offer a new treatment option for those who may have limited choices.
Chengdu, SichuanAges 18–80 - NCT07131059Recruiting
Study for MRD-positive AML in remission
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
Tianjin, Tianjin MunicipalityAges 14 years+ - NCT04061421RecruitingPhase 1/Phase 2
Testing new medicine combos for bone marrow disease overlap syndromes
This early-phase trial studies a new treatment plan (decitabine-related medicine with other targeted drugs, depending on the arm) for adults with MDS/MPN overlap syndromes. It aims to improve control of the disease by targeting the abnormal bone marrow cells. Because it’s Phase 1/2, the main goal is to find safe dosing and see whether it helps responses.
Tampa, FloridaAges 18 years+
Common questions
- Are there clinical trials studying Ruxolitinib?
- Yes. Clin2 currently lists 101 recruiting studies that include Ruxolitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Ruxolitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Ruxolitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Ruxolitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.